Ticker League

Operating Cash Flow for Vertex Pharmaceuticals (VRTX)

As of · Reported

Metric

Latest period

$1.43B

YoY change

-837.2%

5Y CAGR

+2.2%

Peak year (2022)

$4.13B

Operating Cash Flow history chart for Vertex Pharmaceuticals (VRTX) from 1991 to 2025

Latest: $3.63B

Operating Cash Flow growth chart for Vertex Pharmaceuticals (VRTX) from 1991 to 2025

Latest: -837.2%

Operating Cash Flow history table for Vertex Pharmaceuticals (VRTX) from 1991 to 2025

  • 2025$3.63B-837.2%
  • 2024−$492.60M-113.9%
  • 2023$3.54B-14.3%
  • 2022$4.13B+56.2%
  • 2021$2.64B-18.7%
  • 2020$3.25B+107.3%
  • 2019$1.57B+23.5%
  • 2018$1.27B+50.3%
  • 2017$844.94M+257.9%
  • 2016$236.10M-164.6%
  • 2015−$365.43M-28.8%
  • 2014−$513.20M+895.2%
  • 2013−$51.57M-119.3%
  • 2012$267.84M+86.3%
  • 2011$143.74M-122.6%
  • 2010−$635.44M+48.6%
  • 2009−$427.59M+88.8%
  • 2008−$226.48M-10.3%
  • 2007−$252.48M+1023.4%
  • 2006−$22.48M-86.9%
  • 2005−$172.05M+21.0%
  • 2004−$142.16M-15.2%
  • 2003−$167.62M+110.7%
  • 2002−$79.54M+885.1%
  • 2001−$8.07M-51.5%
  • 2000−$16.64M-47.7%
  • 1999−$31.80M+2.3%
  • 1998−$31.10M+230.9%
  • 1997−$9.40M-76.7%
  • 1996−$40.30M+151.9%
  • 1995−$16.00M+8.8%
  • 1994−$14.70M-270.9%
  • 1993$8.60M-262.3%
  • 1992−$5.30M+112.0%
  • 1991−$2.50M—

Operating Cash Flow values are taken from Vertex Pharmaceuticals's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About Operating Cash Flow at Vertex Pharmaceuticals (VRTX)

Operating Cash Flow for Vertex Pharmaceuticals (VRTX): headline value $1.43B · YoY -837.2%. Annual and quarterly series, chart, and tables are below.

Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .

2025's annual operating cash flow for Vertex Pharmaceuticals (VRTX) came in at $3.63B – plunged 837.2% year-over-year.

Over 2020–2025 (5 years), Vertex Pharmaceuticals operating cash flow expanded at a +2.2% compound annual rate, with mixed annual results across the window.

Between 2022 and 2025, Vertex Pharmaceuticals operating cash flow declined 12.1%, falling from $4.13B to $3.63B.

$4.13B stands as the all-time-high annual operating cash flow, posted in 2022, against a low of −$635.44M during 2010.

Vertex Pharmaceuticals Operating Cash Flow by Year

Vertex Pharmaceuticals Operating Cash Flow 2025: $3.63B

In 2025, Vertex Pharmaceuticals reported operating cash flow of $3.63B, plunged 837.2% below 2024.

Vertex Pharmaceuticals Operating Cash Flow 2024: −$492.60M

Vertex Pharmaceuticals operating cash flow in 2024 was −$492.60M, plunged 113.9% below 2023.

Vertex Pharmaceuticals Operating Cash Flow 2023: $3.54B

2023's operating cash flow for Vertex Pharmaceuticals came in at $3.54B, declined 14.3% below 2022.

Vertex Pharmaceuticals Operating Cash Flow 2022: $4.13B

Vertex Pharmaceuticals posted operating cash flow of $4.13B in 2022, surged 56.2% from 2021. This figure represents the highest annual value in the available history.

Vertex Pharmaceuticals Operating Cash Flow 2021: $2.64B

Vertex Pharmaceuticals operating cash flow in 2021 was $2.64B.

See more financial history for Vertex Pharmaceuticals (VRTX).

Sector peers by Operating Cash Flow

Healthcare peers of Vertex Pharmaceuticals (VRTX), ranked by their latest operating cash flow

Frequently asked questions

Vertex Pharmaceuticals (VRTX) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation

Capital Return

No dividends paid by this company.